Literature DB >> 26645139

Functions of microRNA-33a/b and microRNA therapeutics.

Koh Ono1.   

Abstract

Atherosclerosis is a chronic inflammatory disease of the arterial wall. It is characterized by subendothelial accumulation of low-density lipoprotein cholesterol, and its subsequent modification at athero-prone areas leads to further activation of the vascular wall and maintains vascular inflammation. An entirely new level of post-transcriptional gene regulation through microRNA (miR) expression has emerged recently as an important mechanism in the development and progression of numerous diseases, including atherosclerosis. Recently, miR-33a/b have been shown to act as post-transcriptional regulators of lipid metabolism, and their pharmacological inhibition diminished atherosclerosis by raising plasma high-density lipoprotein levels. This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis.
Copyright © 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCA1; Antisense oligonucleotides; HDL-C; Plaque

Mesh:

Substances:

Year:  2015        PMID: 26645139     DOI: 10.1016/j.jjcc.2015.10.017

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  13 in total

1.  Increased expression of miR-33a in monocytes from Mexican hypertensive patients in elevated carotid intima-media thickness.

Authors:  Yazmín Estela Torres-Paz; Claudia Huesca-Gómez; Fausto Sánchez-Muñoz; Rocío Martínez-Alvarado; Ma Elena Soto; Margarita Torres-Tamayo; Giovanny Fuentevilla-Álvarez; Ricardo Gamboa
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

Review 2.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

3.  Epigenetics of Lipid Phenotypes.

Authors:  Sergi Sayols-Baixeras; Marguerite R Irvin; Donna K Arnett; Roberto Elosua; Stella W Aslibekyan
Journal:  Curr Cardiovasc Risk Rep       Date:  2016-08-31

Review 4.  Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.

Authors:  Sarah Costantino; Peter Libby; Raj Kishore; Jean-Claude Tardif; Assam El-Osta; Francesco Paneni
Journal:  Eur Heart J       Date:  2018-12-14       Impact factor: 29.983

Review 5.  Novel Approaches for HDL-Directed Therapies.

Authors:  Jacques Genest; Hong Y Choi
Journal:  Curr Atheroscler Rep       Date:  2017-11-04       Impact factor: 5.113

6.  Effects of trimetazidine on periprocedural microRNA-21 expression by CD4+ T lymphocytes in patients with unstable angina pectoris.

Authors:  Qiang Su; Lang Li; Jinmin Zhao; Yuhan Sun; Huafeng Yang
Journal:  Oncotarget       Date:  2017-09-18

7.  miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Authors:  Omer Faruk Karatas; Jianghua Wang; Longjiang Shao; Mustafa Ozen; Yiqun Zhang; Chad J Creighton; Michael Ittmann
Journal:  Oncotarget       Date:  2017-07-24

8.  Global mapping of miRNA-target interactions in cattle (Bos taurus).

Authors:  Troels K H Scheel; Michael J Moore; Joseph M Luna; Eiko Nishiuchi; John Fak; Robert B Darnell; Charles M Rice
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

9.  The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort.

Authors:  Gilberto Vargas-Alarcón; María Del Carmen González-Salazar; Christian Vázquez-Vázquez; Adrián Hernández-Díaz Couder; Fausto Sánchez-Muñoz; Juan Reyes-Barrera; Sergio A Criales-Vera; Marco Sánchez-Guerra; Citlalli Osorio-Yáñez; Rosalinda Posadas-Sánchez
Journal:  Front Genet       Date:  2021-06-11       Impact factor: 4.599

Review 10.  Advances in HDL: Much More than Lipid Transporters.

Authors:  Soumaya Ben-Aicha; Lina Badimon; Gemma Vilahur
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.